Prognostic Impact of Skeletal Muscle Radiodensity in Advanced Urothelial Carcinoma Undergoing Avelumab Maintenance Therapy
Cancer Diagnosis & Prognosis · 01.07.2026 · 6 (4) · 692-702
DOI: 10.21873/cdp.10569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.07.2026. Verfasst von Nobuhiko Shimizu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/Aim: A significant survival benefit was found for avelumab maintenance therapy versus best supportive care in patients with advanced urothelial carcinoma who attained disease control after platinum-based chemotherapy in the JAVELIN Bladder 100 trial. Although patients generally tolerate avelumab maintenance therapy, some patients experience rapid progression and prognostic factors are not well established. Patients and Methods: In this retrospective study, we investigated the prognostic significance of computed tomography–derived body composition indicators in 57 patients with advanced urothelial carcinoma who received avelumab maintenance therapy after first-line platinum-based chemotherapy. These patients were from within a cohort of 85 patients who underwent first-line platinum-based chemotherapy. Patients were divided into two groups based on a low or high skeletal muscle radiodensity (SMD). Prognostic factors were determined using univariate and multivariate analyses.
Results
Among patients treated with avelumab, median progression-free survival (PFS) was 6.4 months in the high SMD group versus 4.8 months in the low skeletal muscle radiodensity group, while median overall survival (OS) was not reached versus 16.7 months, respectively. In a Cox proportional hazards model, only low SMD indicated a worse prognosis for PFS [hazard ratio (HR)=2.07, 95% confidence interval (CI)=1.06-4.04], while low SMD plus a high neutrophil–lymphocyte ratio were independent predictors for worse OS (HR=2.29, 95%CI=1.04-5.05 and HR=2.44, 95%CI=1.11-5.37, respectively).
Conclusion
SMD is a potential prognostic factor for advanced urothelial carcinoma cases undergoing avelumab maintenance therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
- Department of Experimental Pathology and Tumor Biology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Urology, Kainan Hospital, Yatomi, Japan.
- Department of Urology, Konan Kosei Hospital, Konan, Japan.
- Department of Urology, Northern Mie Medical Center Inabe General Hospital, Inabe, Japan.
Zitieren
APA
Shimizu, N., Naiki, T., Sugiyama, Y., Naiki-Ito, A., Nagai, T., Etani, T., Suzuki, H., Tsubouchi, Y., Morikawa, T., Gonda, M., Aoki, M., Ishikawa, D., Ando, R., & Yasui, T. (2026). Prognostic Impact of Skeletal Muscle Radiodensity in Advanced Urothelial Carcinoma Undergoing Avelumab Maintenance Therapy. Cancer Diagnosis & Prognosis, 6(4), 692-702. https://doi.org/10.21873/cdp.10569
Vancouver
Shimizu N, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, et al. Prognostic Impact of Skeletal Muscle Radiodensity in Advanced Urothelial Carcinoma Undergoing Avelumab Maintenance Therapy. Cancer Diagnosis & Prognosis. 2026;6(4):692-702. doi:10.21873/cdp.10569
BibTeX
@article{Shimizu2026,
author = {Shimizu, Nobuhiko and Naiki, Taku and Sugiyama, Yosuke and Naiki-Ito, Aya and Nagai, Takashi and Etani, Toshiki and Suzuki, Hiroko and Tsubouchi, Yohei and Morikawa, Toshiharu and Gonda, Masakazu and Aoki, Maria and Ishikawa, Daiki and Ando, Ryosuke and Yasui, Takahiro},
title = {Prognostic Impact of Skeletal Muscle Radiodensity in Advanced Urothelial Carcinoma Undergoing Avelumab Maintenance Therapy},
journal = {Cancer Diagnosis & Prognosis},
year = {2026},
volume = {6},
number = {4},
pages = {692--702},
doi = {10.21873/cdp.10569}
}
EUVIMED